急诊阿片类药物过量患者中阿片使用障碍药物治疗的既往使用情况:患病率、误用与过量严重程度
这项前瞻性观察性队列研究纳入2015至2019年两家三级医院急诊科经尿毒理学确认的阿片类药物过量患者696例。17%既往有阿片使用障碍药物(MOUD)处方,2018和2019年患病率显著高于2016年。美沙酮误用风险显著高于其他MOUD,丁丙诺啡调整后与更短住院时间相关。任何MOUD与死亡 odds 降低30%相关但置信区间宽。临床意义在于急诊处方MOUD时需关注美沙酮误用风险。
要点
- 急诊阿片过量患者中17%(120/696)既往有MOUD处方,2018和2019年患病率(20.1%和27.8%)显著高于2016年(8.8%)。
- 美沙酮误用 odds 显著更高(OR 3.96,95%CI 2.57-6.12),丁丙诺啡最低(OR 1.16,p=NS)。
- 美沙酮组平均住院时间3.08天,比丁丙诺啡和纳曲酮(均2.0天)长50%以上(p=NS)。
- 调整混杂后,丁丙诺啡使用与更短住院时间显著相关(IRR -0.44,95%CI -0.85至-0.04)。
- 任何MOUD与死亡 odds 降低30%相关(OR 0.70,95%CI 0.09-5.72),美沙酮组死亡 odds 最高(OR 0.82,95%CI 0.10-6.74)。
适用人群与场景
- 纳入:2015至2019年两家三级医院急诊科经尿毒理学确认的阿片类药物过量患者,年龄≥18岁。
- 排除:替代诊断、数据不足、年龄<18岁、囚犯。
诊断标准与关键阈值
- 阿片类药物过量通过尿毒理学确认。
- 过量严重程度定义:住院时间(天)和院内死亡率。
- MOUD误用 odds 通过OR值评估,美沙酮OR 3.96(95%CI 2.57-6.12),丁丙诺啡OR 1.16(p=NS)。
处置流程与药物剂量
- 原文未提及
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 研究类型:前瞻性观察性队列,两家三级医院,2015-2019年。
- 样本量:2829例急性药物过量急诊患者中,696例确诊阿片过量纳入。
- 主要结果:17%既往有MOUD处方;2018和2019年患病率20.1%和27.8%,显著高于2016年8.8%(p<0.05)。
- 美沙酮误用OR 3.96(95%CI 2.57-6.12),丁丙诺啡OR 1.16(p=NS)。
- 美沙酮组平均住院时间3.08天,丁丙诺啡和纳曲酮组均2.0天(p=NS)。
- 调整后丁丙诺啡与更短住院时间相关(IRR -0.44,95%CI -0.85至-0.04)。
- 任何MOUD死亡OR 0.70(95%CI 0.09-5.72),美沙酮组OR 0.82(95%CI 0.10-6.74)。
证据类型、等级与局限
- 证据类型:前瞻性观察性队列研究。
- 局限:观察性设计不能证明因果关系;仅两家三级医院,可能限制外推性;部分结果置信区间宽(如死亡OR 95%CI 0.09-5.72)。
对床旁实践的改变
- 急诊遇到阿片过量患者应询问MOUD使用情况,尤其美沙酮,因其误用风险高且与更长住院时间相关。
- 既往丁丙诺啡处方与更短住院时间相关,可能影响对住院需求的评估。
- 任何MOUD与死亡风险降低相关但置信区间宽,不能据此改变复苏决策。
指南或共识出处
- Am J Emerg Med
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Medications for opioid use disorder (MOUD) reduce opioid overdose (OD) deaths; however, prevalence and misuse of MOUD in ED patients presenting with opioid overdose are unclear, as are any impacts of existing MOUD prescriptions on subsequent OD severity.
METHODS: This was a prospective observational cohort of ED patients with opioid OD at two tertiary-care hospitals from 2015 to 19. Patients with confirmed opioid OD (via urine toxicology) were included, while patients with alternate diagnoses, insufficient data, age < 18, and prisoners were excluded. OD severity was defined using: (a) hospital LOS (days); and (b) in-hospital mortality. Time trends by calendar year and associations between MOUD and study outcomes were calculated.
RESULTS: In 2829 ED patients with acute drug OD, 696 with confirmed opioid OD were included. Overall, 120 patients (17%) were previously prescribed any MOUD, and MOUD prevalence was significantly higher in 2018 and 2019 compared to 2016 (20.1% and 27.8% vs. 8.8%, p < 0.05). Odds of MOUD misuse were significantly higher for methadone (OR 3.96 95% CI 2.57-6.12) and lowest for buprenorphine (OR 1.16, p = NS). Mean LOS was over 50% longer for methadone (3.08 days) compared to buprenorphine and naltrexone (both 2.0 days, p = NS). Following adjustment for confounders, buprenorphine use was associated with significantly shorter LOS (IRR -0.44 (95%CI -0.85, -0.04)). Odds of death were 30% lower for patients on any MOUD (OR 0.70, 95%CI 0.09-5.72), but highest in the methadone group (OR 0.82, 95%CI 0.10-6.74).
CONCLUSIONS: While MOUD prevalence significantly increased over the study period, MOUD misuse occurred for patients taking methadone, and OD LOS overall was lower in patients with any prior buprenorphine prescription.
参考来源
- Shastry, Nobel, Allen, et al. Prior use of medications for opioid use disorder in ED patients with opioid overdose: prevalence, misuse and overdose severity. Am J Emerg Med. 2021. PMID: 34735968. doi:10.1016/j.ajem.2021.10.012
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。